Song I Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Song I Kim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dong Woon Kim
Department of Oral Anatomy and Neurobiology, Kyung Hee University College of Dentistry, Seoul, Republic of Korea
2 shared publications - Hyo Jung Shin
Department of Medical Science, Chungnam National University, Daejeon 35015, Korea
2 shared publications Jiyong Lee
Department of Anesthesia & Pain Medicine, Chungnam National University School of Medicine, Daejeon, 35015, Republic of Korea
2 shared publications- Juhee Shin
Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015, Korea
2 shared publications - Sun Yeul Lee
Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea
2 shared publications Chan Noh
Department of Anesthesia & Pain Medicine, Chungnam National University School of Medicine, Daejeon, 35015, Republic of Korea
1 shared publication
Latest Publications
- 4 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (25) , 2099-2112
Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting
Aim: Amitriptyline (AMI) has been used to treat neuropathic pain. However, the clinical outcomes remain unsatisfactory, presumably due to a limited understanding of the underlying molecular mechanisms. Here, we investigated a drug repositioning strategy using a low-dose of AMI encapsulated in poly (D, L lactic-co-glycolic acid) (PLGA) nanoparticles (AMI NPs) for neuropathic pain, since PLGA nanoparticles are known to enhance delivery to microglia. Methods: We evaluated the anti-allodynic effects of AMI and AMI NPs on neuropathic pain by assessing behaviors and inflammatory responses in a rat model of spinal nerve ligation (SNL). While the anti-allodynic effect of AMI (30 mu g) drug injection on SNL-induced neuropathic pain persisted for 12 h, AMI NPs significantly alleviated mechanical allodynia for 3 days. Results: Histological and cytokine analyses showed AMI NPs facilitated the reduction of microglial activation and pro-inflammatory mediators in the spinal dorsal horn. This study suggests that AMI NPs can provide a sustained anti-allodynic effect by enhancing the targeting of microglia and regulating the release of pro-inflammatory cytokines from activated microglia. Conclusion: Our findings suggest that the use of microglial-targeted NPs continuously releasing AMI (2 mu g) as a drug repositioning strategy offers long-term anti-allodynic effects.
- 4 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (25) , 2099-2112
Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting
Aim: Amitriptyline (AMI) has been used to treat neuropathic pain. However, the clinical outcomes remain unsatisfactory, presumably due to a limited understanding of the underlying molecular mechanisms. Here, we investigated a drug repositioning strategy using a low-dose of AMI encapsulated in poly (D, L lactic-co-glycolic acid) (PLGA) nanoparticles (AMI NPs) for neuropathic pain, since PLGA nanoparticles are known to enhance delivery to microglia. Methods: We evaluated the anti-allodynic effects of AMI and AMI NPs on neuropathic pain by assessing behaviors and inflammatory responses in a rat model of spinal nerve ligation (SNL). While the anti-allodynic effect of AMI (30 mu g) drug injection on SNL-induced neuropathic pain persisted for 12 h, AMI NPs significantly alleviated mechanical allodynia for 3 days. Results: Histological and cytokine analyses showed AMI NPs facilitated the reduction of microglial activation and pro-inflammatory mediators in the spinal dorsal horn. This study suggests that AMI NPs can provide a sustained anti-allodynic effect by enhancing the targeting of microglia and regulating the release of pro-inflammatory cytokines from activated microglia. Conclusion: Our findings suggest that the use of microglial-targeted NPs continuously releasing AMI (2 mu g) as a drug repositioning strategy offers long-term anti-allodynic effects.
- 20 July 2021
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (18) , 6295-6307
Application of PLGA nanoparticles to enhance the action of duloxetine on microglia in neuropathic pain
Duloxetine (DLX) encapsulated PLGA nanoparticles were applied intrathecally into the spinal cord of spinal nerve ligation-induced neuropathic pain rats. DLX nanoparticles significantly alleviated pain behavior by enhanced targeting of microglia.
- 20 July 2021
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (18) , 6295-6307
Application of PLGA nanoparticles to enhance the action of duloxetine on microglia in neuropathic pain
Duloxetine (DLX) encapsulated PLGA nanoparticles were applied intrathecally into the spinal cord of spinal nerve ligation-induced neuropathic pain rats. DLX nanoparticles significantly alleviated pain behavior by enhanced targeting of microglia.